Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome.

Papps T, McCormack C, Buelens O, Van der Weyden C, Twigger R, Campbell BA, Dickinson M, Prince HM.

Br J Dermatol. 2019 Sep 12. doi: 10.1111/bjd.18522. [Epub ahead of print]

PMID:
31512229
2.

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary Syndrome.

Gao C, McCormack C, van der Weyden C, Goh MS, Campbell B, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM.

Blood. 2019 Aug 29. pii: blood.2019000765. doi: 10.1182/blood.2019000765. [Epub ahead of print]

PMID:
31467061
3.

Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring.

Gilliland WM Jr, Prince HMA, Poliseno A, Kashuba ADM, Rosen EP.

Anal Chem. 2019 Aug 20;91(16):10816-10822. doi: 10.1021/acs.analchem.9b02464. Epub 2019 Aug 6.

PMID:
31345022
4.

Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species.

Thompson CG, Rosen EP, Prince HMA, White N, Sykes C, de la Cruz G, Mathews M, Deleage C, Estes JD, Charlins P, Mulder LR, Kovarova M, Adamson L, Arora S, Dellon ES, Peery AF, Shaheen NJ, Gay C, Muddiman DC, Akkina R, Garcia JV, Luciw P, Kashuba ADM.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaap8758. doi: 10.1126/scitranslmed.aap8758.

PMID:
31270274
5.

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment.

Wong Doo N, White VM, Martin K, Bassett JK, Prince HM, Harrison SJ, Jefford M, Winship I, Millar JL, Milne RL, Seymour JF, Giles GG.

Cancers (Basel). 2019 Jul 2;11(7). pii: E928. doi: 10.3390/cancers11070928.

6.

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, Nelson JAE, Gay CL, Cohen MS, Dumond JB.

Clin Pharmacol Ther. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.

PMID:
31002391
7.

Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP).

Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Poliseno A, Chun TW, Huiting E, Stanczyk FZ, Peery AF, Dellon ES, Adams JL, Gay C, Kashuba ADM.

Clin Infect Dis. 2019 Apr 9. pii: ciz290. doi: 10.1093/cid/ciz290. [Epub ahead of print]

PMID:
30963179
8.

Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Blombery P, Thompson ER, Prince HM.

Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):59S-64S. doi: 10.1097/PRS.0000000000005570. Review.

PMID:
30817557
9.

The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants.

Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, Deva AK.

Plast Reconstr Surg. 2019 May;143(5):1285-1292. doi: 10.1097/PRS.0000000000005500.

PMID:
30789476
10.

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM.

Leuk Lymphoma. 2019 Feb 19:1-12. doi: 10.1080/10428194.2019.1579322. [Epub ahead of print]

PMID:
30777794
11.

Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease.

Scarisbrick JJ, Quaglino P, Prince HM, Kim YH, Willemze R; PROCLIPI investigators.

Br J Dermatol. 2019 May;180(5):1264-1265. doi: 10.1111/bjd.17602. Epub 2019 Jan 27. No abstract available.

PMID:
30604865
12.

Rare T-Cell Subtypes.

van der Weyden C, McCormack C, Lade S, Johnstone RW, Prince HM.

Cancer Treat Res. 2019;176:195-224. doi: 10.1007/978-3-319-99716-2_10.

PMID:
30596220
13.

A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).

Wirth A, Prince HM, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone JM, Davis S, Hertzberg M.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1158-1166. doi: 10.1016/j.ijrobp.2018.12.006. Epub 2018 Dec 13.

PMID:
30553941
14.

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.

Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2019 Apr;60(4):904-911. doi: 10.1080/10428194.2018.1516873. Epub 2018 Dec 14.

PMID:
30547695
15.

Brentuximab vedotin in T-cell lymphoma.

Van Der Weyden C, Dickinson M, Whisstock J, Prince HM.

Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18.

PMID:
30526166
16.

FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformation.

Douglas AP, Atarod M, Prince HM.

Pathology. 2019 Jan;51(1):102-104. doi: 10.1016/j.pathol.2018.08.016. Epub 2018 Nov 22. No abstract available.

PMID:
30471841
17.

Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N.

Nat Genet. 2019 Jan;51(1):196. doi: 10.1038/s41588-018-0304-8.

PMID:
30429576
18.

Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Dumond JB, Greene SA, Prince HM, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JA, Gay CL, Kashuba AD, Cohen MS.

Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.

PMID:
30375984
19.

Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N.

Nat Genet. 2018 Dec;50(12):1650-1657. doi: 10.1038/s41588-018-0251-4. Epub 2018 Oct 29. Erratum in: Nat Genet. 2018 Nov 14;:.

PMID:
30374066
20.

Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Rastogi P, Deva AK, Prince HM.

Curr Hematol Malig Rep. 2018 Dec;13(6):516-524. doi: 10.1007/s11899-018-0478-2. Review.

PMID:
30345474
21.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R.

Br J Dermatol. 2019 Aug;181(2):350-357. doi: 10.1111/bjd.17258. Epub 2018 Nov 25.

PMID:
30267549
22.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

23.

Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.

Prince HM, Querfeld C.

Best Pract Res Clin Haematol. 2018 Sep;31(3):322-335. doi: 10.1016/j.beha.2018.07.007. Epub 2018 Jul 18. Review.

PMID:
30213403
24.

A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.

Wong PKK, Bagga H, Barrett C, Chong G, Hanrahan P, Kodali T, Marabani M, Prince HM, Riordan J, Swarbrick P, White R, Young L.

Curr Rheumatol Rep. 2018 Sep 1;20(10):64. doi: 10.1007/s11926-018-0774-9. Review.

PMID:
30173305
25.

IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.

Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM.

Expert Opin Investig Drugs. 2018 Aug;27(8):691-697. doi: 10.1080/13543784.2018.1498081. Epub 2018 Jul 17. Review.

PMID:
30001170
26.

Psoriasis and cancer. An Australian/New Zealand narrative.

Rademaker M, Rubel DM, Agnew K, Andrews M, Armour KS, Baker C, Foley P, Gebauer K, Goh MS, Gupta M, Marshman G, Prince HM, Sullivan J.

Australas J Dermatol. 2019 Feb;60(1):12-18. doi: 10.1111/ajd.12889. Epub 2018 Jul 10. Review.

PMID:
29992535
27.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2019 Mar 1;30(3):494. doi: 10.1093/annonc/mdy207. No abstract available.

PMID:
29947731
28.

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Fox LC, Yannakou CK, Ryland G, Lade S, Dickinson M, Campbell BA, Prince HM.

Int J Mol Sci. 2018 Jun 13;19(6). pii: E1758. doi: 10.3390/ijms19061758.

29.

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.

Ryland GL, Jones K, Chin M, Markham J, Aydogan E, Kankanige Y, Caruso M, Guinto J, Dickinson M, Prince HM, Yong K, Blombery P.

J Clin Pathol. 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14.

PMID:
29760015
30.

Brentuximab vedotin: targeting CD30 as standard in CTCL.

Prince HM, Gautam A, Kim YH.

Oncotarget. 2018 Feb 10;9(15):11887-11888. doi: 10.18632/oncotarget.24472. eCollection 2018 Feb 23. No abstract available.

31.

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.

Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, Darcy PK, Jenkins MR, Prince HM, Harrison SJ, Quach H, Fairlie DP, Kedzierska K, McCluskey J, Uldrich AP, Neeson PJ, Ritchie DS, Godfrey DI.

Sci Rep. 2018 Mar 7;8(1):4159. doi: 10.1038/s41598-018-22130-1.

32.

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12. Erratum in: Proc Natl Acad Sci U S A. 2019 May 28;116(22):11075-11076.

33.

Blueprint unknown: a case for multidisciplinary management of advanced penile mycosis fungoides.

O'Brien JS, Manning T, Perera M, Prince HM, Lawrentschuk N.

Can J Urol. 2017 Dec;24(6):9139-9144.

PMID:
29260643
34.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2017 Oct 1;28(10):2517-2525. doi: 10.1093/annonc/mdx352.

PMID:
28961843
35.

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM.

Blood Cancer J. 2017 Sep 8;7(9):e603. doi: 10.1038/bcj.2017.85. Review.

36.

Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients.

Oberoi DV, White VM, Seymour JF, Prince HM, Harrison S, Jefford M, Winship I, Hill DJ, Bolton D, Millar J, Wong Doo N, Kay A, Giles G.

Eur J Haematol. 2017 Nov;99(5):423-430. doi: 10.1111/ejh.12941. Epub 2017 Oct 9.

PMID:
28833529
37.

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.

Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A.

Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502.

PMID:
28782211
38.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.

Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.

PMID:
28600132
39.

Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.

Rasmussen TA, McMahon J, Chang JJ, Symons J, Roche M, Dantanarayana A, Okoye A, Hiener B, Palmer S, Lee WS, Kent SJ, Van Der Weyden C, Prince HM, Cameron PU, Lewin SR.

AIDS. 2017 Aug 24;31(13):1839-1845. doi: 10.1097/QAD.0000000000001540.

40.

Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk.

Loch-Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, Connell T, Lofts J, Locke M, Hopper I, Cooter R, Vickery K, Joshi PA, Prince HM, Deva AK.

Plast Reconstr Surg. 2017 Oct;140(4):645-654. doi: 10.1097/PRS.0000000000003654.

PMID:
28481803
41.

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study.

White V, Marco DJT, Bolton D, Davis ID, Jefford M, Hill D, Prince HM, Millar JL, Winship IM, Coory M, Giles GG.

BJU Int. 2017 Nov;120 Suppl 3:6-14. doi: 10.1111/bju.13889. Epub 2017 Jun 9.

42.

Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma.

Blombery P, Prince HM, Seymour JF.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djx010. No abstract available.

PMID:
28376146
43.

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.

Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, Kashuba ADM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.

44.

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DFJ, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR.

AIDS. 2017 May 15;31(8):1137-1141. doi: 10.1097/QAD.0000000000001442.

45.

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.

Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S.

Leuk Lymphoma. 2017 Oct;58(10):2335-2341. doi: 10.1080/10428194.2017.1295143. Epub 2017 Mar 7.

PMID:
28264616
46.

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period.

Oberoi D, White V, Seymour J, Prince HM, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J, Doo NW, Giles G.

J Cancer Surviv. 2017 Jun;11(3):329-338. doi: 10.1007/s11764-016-0591-y. Epub 2017 Jan 31.

PMID:
28144891
47.

Rituximab-induced Crohn's disease.

Varma P, Falconer J, Aga A, Prince HM, Pianko S.

Scand J Gastroenterol. 2017 May;52(5):606-608. doi: 10.1080/00365521.2017.1280530. Epub 2017 Jan 27.

PMID:
28129697
48.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
49.

Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.

Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB.

PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016.

50.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

Supplemental Content

Loading ...
Support Center